AMPK–SQSTM1 Feedback in Metabolic Stress

Metabolic stress is not simply a consequence of tumor growth; it is also a selective pressure that reshapes signaling, autophagy, redox balance, and nutrient utilization. The reference study, Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1/p62 conferring dual activation of AMPK and NFE2L2/NRF2 to synergize antioxidant defense, examines how these responses are coordinated. Published in Autophagy, the work is particularly relevant to tumors with alterations in STK11/LKB1 and KEAP1, where energy-stress signaling and NRF2-mediated antioxidant adaptation may be jointly remodeled.

Study Background and Research Question

Glucose limitation and other forms of nutrient stress reduce metabolic flux, compromise NADPH production, and increase reactive oxygen species. Oxidative damage can then impair mitochondrial respiration and ATP generation, reinforcing the original energy deficit. STK11/LKB1 normally activates AMPK under these conditions, helping cells conserve ATP and preserve redox capacity. In parallel, loss of KEAP1 stabilizes NFE2L2/NRF2, allowing transcription of antioxidant and cytoprotective genes.

The study asks how the STK11–AMPK and KEAP1–NFE2L2 pathways communicate when cells experience metabolic or lysosomal stress. The central question is not merely whether SQSTM1/p62 accumulates, but whether its expression and phosphorylation actively connect energy sensing with antioxidant defense. This is important in STK11-mutant non-small cell lung cancer, where KEAP1 or NFE2L2 alterations may provide compensatory antioxidant capacity.

Key Innovation from the Reference Study

The principal innovation is the identification of a double-positive feedback loop between AMPK and SQSTM1/p62. Metabolic stress increases SQSTM1 expression and phosphorylation. In turn, SQSTM1 activates two protective pathways: it promotes autophagic degradation of KEAP1, thereby enabling NFE2L2/NRF2 activity, and it facilitates formation of the AXIN–STK11–AMPK complex on lysosomal membranes, thereby supporting AMPK activation.

The loop is completed because STK11–AMPK activity is also required for the metabolic-stress-induced increase in SQSTM1 expression and phosphorylation. The resulting circuit is more than parallel activation. It provides a reinforcing mechanism in which energy sensing strengthens p62-dependent signaling, while p62 helps sustain both energy adaptation and antioxidant transcription.

The mechanistic resolution is another important contribution. Low glucose metabolism and AMPK-dependent proton reduction cause lysosomal deacidification. This promotes PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3, transcription factors that increase SQSTM1 expression. Separately, reactive oxygen species and pH-dependent lysosomal calcium release activate MAP3K7/TAK1, which increases SQSTM1 phosphorylation. The authors further identify phosphorylation at S24 and S226 as critical for the dual activation of AMPK and NFE2L2/NRF2, according to the reference study.

Methods and Experimental Design Insights

The experimental design is built around perturbation of metabolic stress, lysosomal function, redox state, and pathway components rather than relying on a single endpoint. The reported experiments use low-nutrient or low-glucose conditions to generate metabolic stress, followed by analysis of SQSTM1 abundance and phosphorylation, AMPK activation, NRF2 pathway status, KEAP1 turnover, and lysosomal signaling events.

Several methodological features strengthen the causal interpretation. Pharmacological disruption of lysosomal acidification with agents such as bafilomycin A1 or concanamycin A was used to test whether lysosomal proton gradients participate in the response. Antioxidant intervention with N-acetylcysteine helped assess the contribution of reactive oxygen species. Immunoprecipitation and protein-interaction analyses addressed formation of signaling complexes, including the AXIN–STK11–AMPK assembly. Genetic or expression-based manipulation of SQSTM1, KEAP1, AMPK, and related regulators helped distinguish pathway dependence from simple correlation.

The study also uses mechanistic contrast conditions. Analysis of lysosomal calcium signaling connects pH changes to TAK1 activation, while examination of TFEB and TFE3 phosphorylation links lysosomal status to SQSTM1 transcription. Testing lactic-acid-derived protons provides an environmental counterpoint: the effects associated with metabolic stress were abrogated when protons were supplied by lactic acid. This distinction is useful because tumor microenvironments can contain both nutrient deprivation and extracellular acidification, and these variables may not produce identical intracellular responses.

Protocol Parameters

• Metabolic-stress condition: Use low-nutrient or low-glucose treatment as the primary perturbation when modeling the energy and lysosomal stress examined in the reference study.
• Pathway readouts: Measure SQSTM1 expression and phosphorylation together with AMPK activation, NRF2 signaling, KEAP1 abundance, and relevant lysosomal markers rather than treating p62 accumulation as a sufficient endpoint.
• Lysosomal mechanism: Include a lysosomal acidification perturbation and assess TFEB/TFE3 phosphorylation to test whether deacidification contributes to SQSTM1 induction.
• Redox and calcium logic: Use antioxidant intervention and, where technically feasible, lysosomal calcium measurements or TAK1 activity assays to separate ROS-dependent from pH-dependent effects.
• Causal p62 analysis: Compare wild-type SQSTM1 with phosphorylation-site variants involving S24 and S226 when determining whether p62 phosphorylation is required for dual pathway activation.
• Environmental contrast: Treat lactic-acid-mediated proton exposure as a distinct condition rather than assuming that all acidic or nutrient-poor environments reproduce the same signaling state.

These parameters summarize the logic of the published experiments and should be adapted to the cell type, stress intensity, and assay platform used in a new study. The reference does not establish one universal treatment schedule or concentration that applies across models.

Core Findings and Why They Matter

First, metabolic stress increased both the amount and phosphorylation of SQSTM1/p62. This positions p62 as an active stress-response node rather than only an autophagy adaptor or marker of impaired autophagic flux.

Second, p62 connected two major protective systems. Its promotion of KEAP1 degradation released NFE2L2/NRF2, increasing the transcriptional antioxidant response. At the lysosome, p62 supported AXIN–STK11–AMPK complex formation, providing a route to AMPK activation during energy stress. The combination is functionally coherent: AMPK helps manage ATP and NADPH economy, whereas NRF2 enhances antioxidant and detoxification capacity.

Third, AMPK was necessary for stress-induced SQSTM1 expression and phosphorylation. This reciprocal dependency explains why the authors describe the mechanism as a double-positive feedback loop. It also offers a conceptual explanation for the coexistence of STK11 and KEAP1 pathway alterations in some tumors. If one arm of adaptation is weakened, selection may favor changes that strengthen the other; if both are active, their cooperation may improve survival under nutrient and oxidative pressure.

Fourth, the work assigns distinct upstream roles to lysosomal events. Deacidification affects TFEB/TFE3 dephosphorylation and SQSTM1 expression, whereas ROS and pH-dependent calcium release activate TAK1 and increase p62 phosphorylation. This separation gives researchers testable intermediate steps and avoids reducing the entire response to a nonspecific oxidative-stress effect.

Finally, the lactic-acid result adds physiological nuance. Proton availability can modify the stress response, meaning that nutrient deprivation in a culture system may not represent the same signaling environment as nutrient deprivation accompanied by tumor-associated acidification. The findings therefore matter both for cancer metabolism research and for the design of experiments that aim to reproduce tumor microenvironmental conditions.

Comparison with Existing Internal Articles

The internal article AMPK–SQSTM1 Feedback Enhances Dual Antioxidant Response in Tumors provides a concise overview of the same study and correctly emphasizes the cooperation between AMPK, SQSTM1/p62, and NFE2L2/NRF2. The reference paper supports that high-level interpretation but adds the mechanistic sequence: lysosomal deacidification influences TFEB/TFE3 and SQSTM1 expression; ROS and lysosomal calcium signaling engage TAK1; and p62 phosphorylation at S24 and S226 is important for downstream activation. Thus, the internal summary is useful for orientation, whereas the primary article is necessary for evaluating experimental controls, pathway perturbations, and the limits of the proposed model.

Limitations and Transferability

The findings should be interpreted primarily as a mechanistic framework derived from cellular metabolic-stress models. They do not, by themselves, establish that the feedback loop has the same magnitude in every tumor lineage, in intact tumors, or in patients with co-occurring STK11 and KEAP1 alterations. Nutrient depletion, lysosomal deacidification, ROS accumulation, and extracellular lactic acid are experimentally separable variables, while they often occur simultaneously in vivo.

SQSTM1 also has multiple functions in autophagy, signaling, and protein aggregation. Consequently, changes in p62 abundance may reflect altered transcription, autophagic turnover, phosphorylation, or combinations of these processes. Interpretation requires flux measurements and pathway-specific controls. Likewise, activation of NRF2 and AMPK can support tumor-cell survival but may have different consequences in stromal, immune, or normal tissue compartments.

Why this cross-domain matters, maturity, and limitations

The reference study concerns tumor metabolic adaptation, whereas TRPV1-focused experiments address ion-channel signaling in sensory neurons and pain mechanisms. These domains should not be conflated: the paper provides no evidence that a TRPV1 antagonist modifies the AMPK–SQSTM1–NRF2 loop, and the findings do not validate a TRPV1 compound as a metabolic-stress intervention. The connection is therefore methodological rather than therapeutic. Researchers studying stress-sensitive calcium signaling may find conceptual parallels, but any bridge between tumor lysosomal signaling and sensory neuron signaling studies remains exploratory and requires direct validation.

Research Support Resources

For a separate TRPV1-centered workflow, researchers can use AMG 9810 (SKU B7018), a selective competitive TRPV1 antagonist, to support pain mechanism research and sensory neuron signaling studies. It can be incorporated into an inhibition of capsaicin-induced calcium influx experiment or a CGRP release inhibition assay, but these are distinct assays from the metabolic-stress experiments discussed above. The product information reports solubility at concentrations of at least 33.7 mg/mL in DMSO and recommends storage at −20°C; solution stability and vehicle controls should be considered during assay planning.